Condition
Neoplasms, Brain
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Completed2
Terminated1
Withdrawn1
Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03911388Phase 1RecruitingPrimary
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT04657315Phase 1Completed
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
NCT01677741Phase 1CompletedPrimary
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
NCT02692898Terminated
Biomarker Analysis of Central Nervous System Tumors
NCT01445691Phase 2Withdrawn
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Showing all 5 trials